CN115925983A - Gdf15融合蛋白及其用途 - Google Patents

Gdf15融合蛋白及其用途 Download PDF

Info

Publication number
CN115925983A
CN115925983A CN202211012940.3A CN202211012940A CN115925983A CN 115925983 A CN115925983 A CN 115925983A CN 202211012940 A CN202211012940 A CN 202211012940A CN 115925983 A CN115925983 A CN 115925983A
Authority
CN
China
Prior art keywords
seq
amino acid
gdf15
variant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211012940.3A
Other languages
English (en)
Chinese (zh)
Inventor
燕江雨
操蓉波
肖�琳
曾君南
黄丽玫
危喜玲
李钊锋
龚庆伟
闫兴国
李静
黄丹霞
陈小锋
李文佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN115925983A publication Critical patent/CN115925983A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202211012940.3A 2021-08-24 2022-08-23 Gdf15融合蛋白及其用途 Pending CN115925983A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110977378 2021-08-24
CN2021109773787 2021-08-24

Publications (1)

Publication Number Publication Date
CN115925983A true CN115925983A (zh) 2023-04-07

Family

ID=85321545

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202211012940.3A Pending CN115925983A (zh) 2021-08-24 2022-08-23 Gdf15融合蛋白及其用途
CN202211013315.0A Pending CN115925984A (zh) 2021-08-24 2022-08-23 Gdf15融合蛋白及其用途
CN202211012820.3A Pending CN115925982A (zh) 2021-08-24 2022-08-23 Gdf15融合蛋白及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202211013315.0A Pending CN115925984A (zh) 2021-08-24 2022-08-23 Gdf15融合蛋白及其用途
CN202211012820.3A Pending CN115925982A (zh) 2021-08-24 2022-08-23 Gdf15融合蛋白及其用途

Country Status (8)

Country Link
US (3) US20240391971A1 (https=)
EP (3) EP4393940A4 (https=)
JP (1) JP2024532882A (https=)
KR (1) KR20240049337A (https=)
CN (3) CN115925983A (https=)
AU (1) AU2022333099A1 (https=)
CA (1) CA3226178A1 (https=)
WO (3) WO2023025120A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CA2919076C (en) * 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CR20200510A (es) * 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
PE20221316A1 (es) * 2019-10-15 2022-09-07 Dragonfly Therapeutics Inc Proteinas que se unen a nkg2d, cd16 y flt3
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
JP2025504612A (ja) * 2021-12-31 2025-02-13 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用

Also Published As

Publication number Publication date
EP4393941A1 (en) 2024-07-03
EP4393941A4 (en) 2025-10-15
EP4392461A1 (en) 2024-07-03
KR20240049337A (ko) 2024-04-16
JP2024532882A (ja) 2024-09-10
CN115925984A (zh) 2023-04-07
WO2023025123A1 (zh) 2023-03-02
AU2022333099A1 (en) 2024-02-08
EP4392461A4 (en) 2025-10-15
WO2023025129A1 (zh) 2023-03-02
EP4393940A4 (en) 2025-10-15
EP4393940A1 (en) 2024-07-03
US20240343770A1 (en) 2024-10-17
US20240350588A1 (en) 2024-10-24
CA3226178A1 (en) 2023-03-02
WO2023025120A1 (en) 2023-03-02
US20240391971A1 (en) 2024-11-28
CN115925982A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
US20250084144A1 (en) Dual-target fusion proteins comprising fgf21 and glp-1, connected through a fc portion of an immunoglobulin
JP6182600B2 (ja) 線維芽細胞増殖因子２１タンパク質
KR20150093167A (ko) 비만 치료를 위한 글루카곤/glp-1 작용제
EA032727B1 (ru) Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2018032787A1 (zh) 高糖基化人生长激素融合蛋白及其制备方法与用途
CN113292646B (zh) Glp-1/胰高血糖素双重激动剂融合蛋白
US20180280474A1 (en) Treatment of bile acid disorders
CN114591415A (zh) Glp-1/gcg双受体激动剂多肽及其融合蛋白
WO2023280133A1 (zh) 融合蛋白及其应用
US20250179142A1 (en) Fusion protein of glp-1 and gdf15 and use thereof
TW202216747A (zh) 包含類升糖素胜肽—１及介白素—１受體拮抗物的融合蛋白及其用途
CN115925983A (zh) Gdf15融合蛋白及其用途
CN116948037A (zh) 一种新结构长效卵泡刺激素重组蛋白及其制备和应用
CA2469724A1 (en) Mutant glycoproteins
WO2024131534A1 (zh) 异源二聚体Fc融合蛋白及其用途
WO2008032059A2 (en) Growth factor
HK40015284A (en) Dual-target fusion proteins comprising the fc portion of an immunoglobulin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination